This meeting represents the first positive phase 3 announcement for any personalized neoantigen therapy based on messenger ribonucleic acid.
Article Index:
- Announcement of phase 3 data review in Madrid
- INTERPATH-001 trial results and the decisive statistical improvement
- Five-year follow-up and a 49 percent reduction in mortality risk
- Vaccine mechanism of action and encoding of 34 personalized tumor neoantigens
- Market expectations and estimated sales value of $12 billion
- Presidential symposium timeline and anticipated regulatory pathway
- Frequently asked questions
Announcement of phase 3 data review in Madrid
Leading American biotechnology research company Moderna announced on Monday that the latest critical phase 3 clinical data for its personalized mRNA immunotherapy and genetic cancer treatment, known as “intismeran autogen,” will be officially reviewed in a special presidential session during the European Society for Medical Oncology congress held in Madrid, Spain.
The clinical presentation, accompanied by a live interactive video broadcast for investors and physicians, is scheduled for Saturday, October 24. Three research abstracts prepared by the company in collaboration with pharmaceutical giant Merck have been accepted to cover phase 3 studies in melanoma and non-small cell lung cancer, alongside a phase 1 study for aggressive pancreatic cancer.
INTERPATH-001 trial results and the decisive statistical improvement
The anticipated data are based on the positive initial results of the large-scale phase 3 clinical trial “INTERPATH-001,” which included 1,137 patients who underwent complete surgical resection of advanced cutaneous melanoma tumors across stages II, III, and IV.
Pre-specified interim statistical analysis showed that combining the innovative intismeran vaccine with Merck’s well-known immunotherapy drug Keytruda (pembrolizumab) achieved a statistically highly significant improvement in recurrence-free survival, alongside a decisive improvement in distant metastasis-free survival compared to using Keytruda alone. This marks the first completed phase 3 clinical success for any personalized cancer vaccine relying on mRNA technology in medical history.
Five-year follow-up and a 49 percent reduction in mortality risk
This achievement reinforces the long-term five-year clinical follow-up data from the phase 2 trial, which was presented at the American Society of Clinical Oncology annual meeting earlier this year. The figures proved a 49 percent reduction in the risk of tumor recurrence or death in patients who received the combination therapy compared to monotherapy.
Careful follow-up also showed a massive 59 percent decrease in the risk of malignant tumor spread and metastasis to vital distant organs in the body, giving physicians and oncology patients real, tangible hope in overcoming fatal cancer relapses and turning it into a manageable disease that can be definitively cured.
Vaccine mechanism of action and encoding of 34 personalized tumor neoantigens
The scientific concept behind the “intismeran” treatment is based on decoding each individual patient’s unique tumor. The company conducts high-precision genetic analysis of the resected tumor biopsy to identify unique mutations, manufacturing a personalized vaccine that encodes up to 34 new tumor neoantigens specific to that exact patient.
These genetic instructions stimulate the body’s immune system and T memory cells to recognize stray cancer cells, hunt them down, and destroy them with surgical precision without harming healthy tissue. The U.S. Food and Drug Administration has granted this treatment “Breakthrough Therapy” designation to support expediting its approval pathways for high-risk melanoma after surgery.
Market expectations and estimated sales value of $12 billion
Moderna and Merck are currently expanding into nine advanced phase 2 and phase 3 clinical trials to test the vaccine in bladder, kidney, colon, breast, and prostate tumors. Bloomberg Intelligence research units estimated that the vaccine’s annual sales could reach $12 billion by 2040 in the most optimistic scenarios, and nearly $5.4 billion according to risk-adjusted estimates.
This economic growth reflects a broad boom in the therapeutic cancer vaccine market, which was valued at $335 million in 2025. DelveInsight reports project it to grow at a compound annual rate of 36 percent through 2036, driven by the successes of RNA technologies and precision medicine.
Presidential symposium timeline and anticipated regulatory pathway
The global ESMO medical congress will be held in Madrid from October 23 to 27. Dr. Georgina Long, a prominent professor and melanoma research expert from the Melanoma Institute Australia in Sydney, will present the study’s critical clinical data at the presidential symposium, which is receiving massive international media and medical attention.
Although the treatment is still in the investigative trial stage and has not yet received final commercial authorization from regulatory agencies in the United States and Europe, the anticipated positive results may pave the way for submitting fast-track application requests to obtain official approvals and begin distributing it in global hospitals over the next year.
Frequently asked questions
Question: What is the historical milestone achieved by Moderna’s personalized cancer vaccine in phase 3?
Answer: It is the first personalized treatment relying on mRNA to prove successful in improving recurrence-free and metastasis-free survival.
Question: How is the intismeran vaccine manufactured in a personalized manner for each tumor patient?
Answer: The patient’s biopsy is genetically analyzed, and up to 34 unique tumor mutations are encoded to stimulate immune cells to destroy the tumor accurately.
Question: What is the percentage decrease in the risk of death or disease recurrence according to long-term follow-up studies?
Answer: Five-year follow-up showed a 49 percent decrease in the risk of relapse and death, and a 59 percent decrease in the spread of distant tumors.
